Figure 1.

Chemical structures of platinum anticancer agents. Cisplatin, carboplatin, and oxaliplatin are FDA-approved for chemotherapy use in the United States. Satraplatin was the first Pt(IV) complex to reach Phase III clinical trials as an orally available platinum compound. cDPCP is a non-classical, monofunctional platinum complex with anti-tumor activity in colorectal cancer cells that inhibits transcription in vitro.